Johnson & Johnson (JNJ)

How JNJ actually reacts to news — the realized, point-in-time move the market made, measured across 2,000+ labeled events over the last three years with zero look-ahead.

Track JNJ free See the full JNJ reaction history →

The quantified answer

JNJ’s median reaction, across the day.

+0.06%

Median 30-min

Typical reaction 30 minutes after any JNJ news

56%

Moved up

Share of JNJ news events that rose at 30 minutes

+0.06%

Median to close

Where JNJ typically settles by the closing bell

Median move vs. the price at the news timestamp, across 2,000+ labeled events.

By event type

How JNJ reacts, by analyst action.

Event	Events	Median 30-min	% positive	Median to close
Analyst upgrades	40	+0.14%	60%	+0.55%
Analyst downgrades	30	-0.13%	47%	+0.22%
Coverage initiations	15	+0.15%	60%	+0.45%
Rating reiterations	230	+0.01%	50%	-0.03%
Price-target raises	73	-0.03%	45%	-0.09%
Price-target cuts	23	+0.10%	61%	-0.02%

Last 3 years, pulled 2026-07-14. Reaction = percent move vs. the price at the news timestamp. The same measurement runs across every name in the dataset.

That’s how JNJ usually reacts — get an email when it moves on news →

Next time, know first

Email me when JNJ moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to JNJ’s baseline. Nothing else.

Prefer a one-pager?

Get “How JNJ reacts to news” as a PDF.

A free one-page summary: JNJ’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.

Recent JNJ events, each with its measured reaction. (Page 1 of 10.)

Date	Headline	Event	Source	5-min	To close
Aug 11, 2026	Form N-PX JOHNSON & JOHNSON For: Jun 30	SEC filing · Form N-PX	SEC EDGAR	+0.28%	-0.39%
Aug 11, 2026	Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive Year	Press release	PR Web	+0.28%	-0.39%
Aug 6, 2026	Form 13F-HR JOHNSON & JOHNSON For: Jun 30	SEC filing · Form 13F-HR	SEC EDGAR	-0.09%	+0.42%
Aug 4, 2026	Form 8-K JOHNSON & JOHNSON For: Aug 04	SEC filing · Form 8-K	SEC EDGAR	-1.31%	+0.20%
Aug 4, 2026	Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference	Press release	Business Wire	+0.55%	+0.92%
Aug 4, 2026	Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September	Press release	Business Wire	-1.31%	+0.20%
Jul 30, 2026	Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer	Press release	PR Newswire	+0.15%	-1.24%
Jul 29, 2026	Form 8-K JOHNSON & JOHNSON For: Jul 29	SEC filing · Form 8-K	SEC EDGAR	+0.15%	-1.24%
Jul 29, 2026	Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset	Press release	Business Wire	+0.15%	-1.24%
Jul 29, 2026	Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation	Press release	Business Wire	+0.15%	-1.24%
Jul 28, 2026	Form 8-K JOHNSON & JOHNSON For: Jul 27	SEC filing · Form 8-K	SEC EDGAR	+0.64%	-1.21%
Jul 27, 2026	Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation	Press release	Business Wire	+0.64%	-1.21%
Jul 23, 2026	Form 10-Q JOHNSON & JOHNSON For: Jun 28	SEC filing · Form 10-Q	SEC EDGAR	-0.52%	+0.75%
Jul 23, 2026	TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma	Press release	PR Newswire	+1.05%	+1.58%
Jul 22, 2026	Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System	Press release	Business Wire	+0.02%	+1.14%
Jul 16, 2026	DePuy Synthes Acquires Expanding Innovations™	Press release	Business Wire	+0.05%	+0.55%
Jul 16, 2026	Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award	Press release	Business Wire	+0.05%	+0.55%
Jul 15, 2026	Form 8-K JOHNSON & JOHNSON For: Jul 15	SEC filing · Form 8-K	SEC EDGAR	+2.13%	-0.80%
Jul 15, 2026	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026	Press release	Business Wire	+2.13%	-0.80%
Jul 15, 2026	Johnson & Johnson reports Q2 2026 results, raises 2026 outlook	Press release	Business Wire	+2.13%	-0.80%
Jul 9, 2026	Products That Count Announces Winners of the 2026 Q2 Product Awards in Fintech, Cybersecurity, and Healthcare	Press release	PR Web	+0.10%	+0.18%
Jul 8, 2026	Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform	Press release	Business Wire	-0.34%	-1.72%
Jun 26, 2026	Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis	Press release	PR Newswire	+0.15%	+0.67%
Jun 25, 2026	Form 11-K JOHNSON & JOHNSON For: Dec 31	SEC filing · Form 11-K	SEC EDGAR	+0.68%	+2.62%
Jun 15, 2026	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida	Press release	Business Wire	-2.04%	-1.40%
Jun 13, 2026	New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma	Press release	PR Newswire	-2.04%	-1.40%
Jun 11, 2026	IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies	Press release	PR Newswire	+0.18%	-0.70%
Jun 11, 2026	Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients	Press release	Business Wire	+0.18%	-0.70%
Jun 10, 2026	Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial	Press release	Business Wire	-0.04%	-0.47%
Jun 8, 2026	Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform	Press release	Business Wire	+0.65%	-0.26%
Jun 3, 2026	Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study	Press release	PR Newswire	+0.59%	+0.35%
Jun 3, 2026	Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease	Press release	PR Newswire	+0.59%	+0.35%
May 31, 2026	Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm	Press release	PR Newswire	-0.50%	+0.14%
May 31, 2026	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited	Press release	PR Newswire	-0.50%	+0.14%
May 29, 2026	New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma	Press release	PR Newswire	-0.30%	-2.55%
May 29, 2026	RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer	Press release	PR Newswire	+0.23%	-0.04%
May 28, 2026	FDA approves label expansion, cementing TREMFYA® as the only IL-23 inhibitor proven to help stop further joint damage	Press release	PR Newswire	-0.30%	-2.55%
May 27, 2026	Form SD JOHNSON & JOHNSON	SEC filing · Form SD	SEC EDGAR	-0.02%	-0.09%
May 27, 2026	Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	Press release	Business Wire	-0.02%	-0.09%
May 26, 2026	DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio	Press release	Business Wire	-0.49%	-1.21%
May 26, 2026	DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS	Press release	Business Wire	-0.49%	-1.21%
May 14, 2026	Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation	Press release	PR Newswire	+0.38%	-1.76%
May 13, 2026	Form 13F-HR JOHNSON & JOHNSON For: Mar 31	SEC filing · Form 13F-HR	SEC EDGAR	-0.65%	-0.09%
May 12, 2026	Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter	Press release	Business Wire	-0.04%	+0.54%
May 11, 2026	Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP	Press release	PR Newswire	+0.10%	+0.05%
May 11, 2026	Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	Press release	Business Wire	-0.04%	+0.54%
May 7, 2026	Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission	Press release	PR Newswire	-0.70%	-1.01%
May 5, 2026	Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System	Press release	Business Wire	-0.01%	+0.07%
May 5, 2026	Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease	Press release	PR Newswire	-0.01%	+0.07%
May 5, 2026	Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease	Press release	PR Newswire	-0.01%	+0.07%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Keep exploring

More of the dataset.

JNJ earnings → · Analyst actions → · SEC filings → · Full history →

Every ticker we measure the same way24

Johnson & Johnson (JNJ)

JNJ’s median reaction, across the day.

How JNJ reacts, by analyst action.

Email me when JNJ moves on news.

Get “How JNJ reacts to news” as a PDF.

Recent JNJ events, each with its measured reaction. (Page 1 of 10.)

More of the dataset.

Apple (AAPL)

NVIDIA (NVDA)

Tesla (TSLA)

Microsoft (MSFT)

Advanced Micro Devices (AMD)

Amazon (AMZN)

Alphabet (GOOG)

Meta Platforms (META)

Broadcom (AVGO)

JPMorgan Chase (JPM)

Visa (V)

Walmart (WMT)

Eli Lilly (LLY)

UnitedHealth Group (UNH)

Netflix (NFLX)

Exxon Mobil (XOM)

Home Depot (HD)

Costco (COST)

Mastercard (MA)

Oracle (ORCL)

Salesforce (CRM)

Bank of America (BAC)

Coca-Cola (KO)

Walt Disney (DIS)

Browse all tickers

You just saw one reaction.
There are 26 million more.

Know the next move, measured.

The dataset, one command away.

Johnson & Johnson (JNJ)

JNJ’s median reaction, across the day.

How JNJ reacts, by analyst action.

Email me when JNJ moves on news.

Get “How JNJ reacts to news” as a PDF.

Recent JNJ events, each with its measured reaction. (Page 1 of 10.)

More of the dataset.

Apple (AAPL)

NVIDIA (NVDA)

Tesla (TSLA)

Microsoft (MSFT)

Advanced Micro Devices (AMD)

Amazon (AMZN)

Alphabet (GOOG)

Meta Platforms (META)

Broadcom (AVGO)

JPMorgan Chase (JPM)

Visa (V)

Walmart (WMT)

Eli Lilly (LLY)

UnitedHealth Group (UNH)

Netflix (NFLX)

Exxon Mobil (XOM)

Home Depot (HD)

Costco (COST)

Mastercard (MA)

Oracle (ORCL)

Salesforce (CRM)

Bank of America (BAC)

Coca-Cola (KO)

Walt Disney (DIS)

Browse all tickers

You just saw one reaction.There are 26 million more.

Know the next move, measured.

The dataset, one command away.

You just saw one reaction.
There are 26 million more.